Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
51.02
+0.91 (1.82%)
May 27, 2026, 4:00 PM EDT - Market closed
Vaxcyte Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Vaxcyte stock has a consensus rating of "Strong Buy" and an average price target of $109. The average 1-year stock price forecast is 113.64% higher than the current stock price, while the lowest is $67 (+31.32%) and the highest is $163 (+219.48%).
Price Target: $109 (+113.64%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vaxcyte stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 21, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $116 | Buy | Reiterates | $116 | +127.36% | May 8, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
| Needham | Needham | Buy Reiterates $110 | Buy | Reiterates | $110 | +115.60% | May 7, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $75 | Buy | Maintains | $75 | +47.00% | May 6, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
79.05M
EPS This Year
-8.20
from -5.63
EPS Next Year
-6.87
from -8.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 651.0M | ||||||
| Avg | n/a | 79.1M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -6.53 | -1.62 | ||||||
| Avg | -8.20 | -6.87 | ||||||
| Low | -9.61 | -11.24 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.